Kornimate/medical-research-clean huggingface dataset:
the clinical efficacy and safety of skinstylus microneedling system

Conditions: Cicatrix, Hypertrophic

Summary: the purpose of the trial is to provide objective evidence the skinstylus may be used safely and effectively for the treatment of ventral torso hypertrophic scars.

1. the skinstylus has been designated as a non-significant risk and therefore will be granted an investigational device exemption (ide). there are no meaningful changes to the skinstylus® instructions for use and specifically no new risks will be introduced. 2. each participant shall have at least one suitable ventral torso hypertropic scar of sufficient length that it may be easily visualized in two halfs. at the conclusion of the trial all participants shall be provided with a cross over treatment on the non-treated portion of the scar identical to that which was provided within the trial for the purpose of "evening" the ventral torso hypertrophic scar. this is entirely voluntary and participants may decline the treatment if they wish.

Eligibility criteria:
inclusion criteria: 1. at least 23 years old 2. shall have at least one suitable ventral torso hypertropic scar of sufficient length that it may be easily visualized in two halfs. 3. the scar(s) must present along a flat surface suitable for application of the skinstylus® device and consistent medical photography. exclusion criteria: 1. pregnancy or chance of pregnancy 2. currently taking coumadin/warfarin® or heparin 3. diagnosis of any type of bleeding disorder 4. any history of keloid formation 5. lidocaine, tetracaine, prilocaine, bupivacaine, or benzocaine hypersensitivity 6. diagnosis of mental disorders requiring inpatient treatment 7. presence of metal implants around the proposed treatment areas 8. diagnosis of any undefined wasting disease (cachexia for example) 9. diagnosis of an active infection in the treatment area other than mild acne 10. diagnosis of the presence of tumors or those who are being treated by chemotherapy or radiation therapy 11. diagnosis of severe cardiovascular and cerebrovascular disease 12. diagnosis of renal failure
hypomagnesemia associated with proton-pump inhibitor use

Conditions: Proton Pump Inhibitor Adverse Reaction; Hypomagnesemia; Arrhythmias, Cardiac; Seizures; Hypocalcemia; Hypokalemia

Summary: use of proton pump inhibitors has been associated with hypomagnesemia. however, various case-control or prospective studies have found conflicting results with regards to proton pump inhibitors use and development of hypomagnesemia. our aim was to evaluate the likelihood that proton pump inhibitors contributed to severe hypomagnesemia in a retrospective cohort of patients admitted with severe hypomagenesemia. we also aimed to look for risk factors leading to development of hypomagnesemia amongst users of proton pump inhibitors


Eligibility criteria:
inclusion criteria: * patients admitted with hypomagnesemia (cases) * patients prescribed with proton pump inhibitors (controls) exclusion criteria: * patients prescribed with less than three months duration of proton pump inhibitors (controls)
olanzapine treated adolescents with schizophrenia or bipolar i disorder

Conditions: Schizophrenia; Bipolar Disorder

Summary: the purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender, origin, and smoking status on olanzapine pharmacokinetics in adolescents with schizophrenia or bipolar i disorder. this study will also assess the safety of olanzapine delivered orally.


Eligibility criteria:
inclusion criteria: * male or female patients, 13 through 17 years of age (must not have reached their 18th birthday prior to visit 1). * female patients must not be pregnant or nursing. * patient and patient's parent/authorized legal representative must have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must have given informed consent. * patient must have a previously documented diagnosis of schizophrenia or bipolar i according to the dsm-iv-tr, and either confirmed previously by k-sads-pl or be confirmed by k-sads-pl at visit 1. exclusion criteria: * patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or bipolar i disorder. * patients are not allowed into the study if they currently meet the criteria for the depressed phase of bipolar disorder or are diagnosed with bipolar ii disorder.
efficacy of low-dose intra-articular tranexamic acid in total knee replacement

Conditions: Primary Osteoarthritis of Knee Nos

Summary: the purpose of this study is to determine 1) the effective dosage of intra-articular tranexamic acid injection for controlling blood loss and blood transfusion requirement in conventional total knee replacement, and 2) whether the blood loss reduction effect depended on the dose of tranexamic acid used.


Eligibility criteria:
inclusion criteria: * patients diagnosed as primary knee osteoarthritis and underwent unilateral primary cemented conventional total knee replacement * no risk of abnormal bleeding tendency or bleeding disorder (normal coagulogram, serum creatinine \< 2.0 mg/dl, stop nonsteroidal anti-inflammatory drugs and antiplatelet drugs more than 7 days * no contra-indication for tranexamic acid use (no active intravascular clotting process, no acquired defective colour vision, no subarachnoid hemorrhage, no hypersensitivity to txa, and no any of history of serious adverse effects, thrombotic disorder and hematuria) exclusion criteria: * incomplete data collection, for example, malfunctioned drain or accidental drain removal.
satisfaction of limited english-proficient patients with phone interpretation services compared to in-person interpreters: a randomized controlled trial

Conditions: Pelvic Floor Disorders

Summary: the aim of the study is to determine if in-person interpreters increases patient satisfaction of urgyn office visits compared to the use of phone interpreter services for limited english proficient (lep) patients

this study is a randomized controlled trial. patients presenting to the umass memorial urogyn clinic will be screened for eligibility using the inclusion and exclusion criteria. lep patients will be identified as patients that initiate conversation in a non-english language and are only able to communicate adequately regarding their medical problem in a non-english language. after patients have been seen for their scheduled office visit, they will be invited to participate in the study. once the patient has agreed to participate in the study the participant will be randomized. study assignment will be revealed using sequentially numbered sealed opaque envelopes. randomization will be performed using software and a block randomization scheme to yield a 50% chance of having an in-person interpreter. those assigned to the control group will receive phone translation services and the experimental group will have in person interpreters. at the subsequent visit, demographic information will be collected and patients will then receive interpretation services from the phone or an in-person interpreter.

Eligibility criteria:
inclusion criteria: * lep speaking spanish and portuguese female patients presenting to the u mass urogyn clinic with or without ad-hoc interpreters * spanish and portuguese speaking female patients with lep presenting to the u mass urogyn clinic for an office visit of any type exclusion criteria: * unable to provide consent * under 18 years of age * pregnant women * prisoners * lep subjects who decline interpreter services * non -spanish or non - portuguese speaking subjects * patients with cognitive impairment * visually or hearing impaired patients * patients not requiring a follow up appointment

Keywords: quality care access to health care interpretation services
study of ticilimumab in patients with metastatic colorectal cancer whose disease had progressed after treatment

Conditions: Colorectal Neoplasms

Summary: this study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. patients who are intolerant to treatment(s) are also included. this is a study for good performance status colorectal cancer patients who have exhausted standard therapy options.


Eligibility criteria:
inclusion criteria: * radiographic evidence of metastatic, progressive disease following standard therapies. * eastern cooperative oncology group (ecog) performance status 0-1. exclusion criteria: * known brain metastases or uncontrolled pleural effusions. * history of chronic inflammatory or autoimmune disease.
effects of fish-oil on mood and cognitive functions of healthy individuals

Conditions: Depression

Summary: the investigators recently found a positive effect of omega-3 supplements on cognitive function in healthy individuals after 4 weeks (j of psychopharmacology 2009, 23: 831-840). the investigators hypothesize that 4 weeks consumption of omega-3 supplements in previously depressed individuals will positively affect their cognitive functions. secondly, low heart rate variability (hrv) is a risk factor for cardiovascular disease. some studies have found low hrv in patients with depression. no studies have investigated the effects of omega-3 fatty acid supplements on heart rate variability in individuals with a history of depression. the investigators will test the hypotheses that omega-3 supplements lead to an improvement of heart rate variability indices in healthy volunteers with a history of depression.


Eligibility criteria:
inclusion criteria: * dutch-speaking men and women * normal weight (bmi between 18 and 27). * regular diets, not containing fish more than once a week. * history of depression (at least one major depressive episode in the past). exclusion criteria: * currently more than mildly depressed (bdi-ii-nl score higher than 19, or score on the suicidality item of this scale higher than 1). * current or past psychosis * current substance abuse or past substance dependence * smoking or current use of soft drugs (current = month prior to study till completion) * any hard drug use (lifetime) * more than 3 alcoholic consumptions/day participants will be asked to keep their dietary habits constant throughout the study.

Keywords: depression cognition heart rate variability omega-3 fatty acids depression (in remission) (vulnerability to depression)
study of reactogenicity, safety, immunogenicity, and pock lesion formation of a cell-cultured smallpox vaccine compared to dryvax®

Conditions: Smallpox

Summary: this study will evaluate the safety and efficacy of both dryvax® and the new cell-cultured vaccine (ccsv) in a comparative fashion. across 3 cohorts, 150 vaccinia-naive volunteers will be randomly assigned to receive either ccsv (100 volunteers) or dryvax® (50 volunteers) in a blinded fashion. subjects will be followed closely for up to 6 months and a subgroup of volunteers will be followed up to 3 years in order to evaluate the duration of immunity following vaccination. another cohort will enroll 100 vaccinia-experienced volunteers and randomly assign them to receive either ccsv (50 volunteers) or dryvax® (50 volunteers) and a sub group will be followed up to 3 years. a fifth cohort will enroll 100 vaccinia-naive volunteers and randomly assign them to receive different dilutions of ccsv (1:1, 1:5, 1:25, and 1:50).


Eligibility criteria:
* have never received smallpox vaccine or previously received an experimental smallpox vectored vaccine (for vaccinia-naive cohorts only) * have been previously vaccinated within the last 10 years (vaccinia-experienced cohort only) * must agree to have blood samples banked for future research testing * have not participated in any clinical trial using investigational product within past month * no current or past history of exfoliative skin problems * not have regular contact with children under 3 years of age until scab at site of vaccination has fallen off (around 21 days or 3 weeks after vaccination) * do not have a positive test for hiv virus, hepatitis c virus, or hepatitis b surface antigen * are not a health care worker caring for newborns, patients that are immunocompromised or have skin that is adversely altered * will not engage in direct patient care until immunization scab falls off (around 21 days or 3 weeks after vaccination) if health care worker

Keywords: smallpox smallpox vaccine vaccinia
french observational study with colic capsule

Conditions: Colic Capsule Interest

Summary: colic capsule usings with patients without possible colic endoscopy


Eligibility criteria:
inclusion criteria: * anesthesia not possible * incomplete colic endoscopy * colic endoscopy refused exclusion criteria: * none
role of intralesional combined injection of furosemide and digoxin in cutaneous warts at tertiary care hospital in karachi.

Conditions: Cutaneous Warts

Summary: identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in karachi, pakistan.

cutaneous warts are benign growth caused by human papilloma virus. virus have more than 100 types of which few are responsible for cutaneous disease. both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (na+/k+-atpase and na+-k+-2cl-co-transporter-1) thereby causing delay in viral replication. the purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Eligibility criteria:
inclusion criteria: 1. patients presenting with greater than or equal to two warts 2. either gender. 3. age 18 - 60 years. - exclusion criteria: 1. pregnant or lactating women. 2. patient not giving informed consent. 3. patient received any treatment in the last 3 months period. 4. patient with acute illness and immuno-suppressive disease. 5. patient taking immuno-suppressive drugs. 6. patient having hypersensitivity to any investigational medicine. 7. patient having cutaneous warts on face and genitals. 8. patient having cardiovascular disease. 9. patient having renal disease. -

Keywords: cutaneous warts furosemide digoxin
cohort study on biomarkers and clinical treatment of tinnitus

Conditions: Tinnitus, Subjective; Acoustic Stimulation; Transcranial Magnetic Stimulation, Repetitive; Magnetoencephalography

Summary: the goal of this clinical trial is to search for biomarkers in tinnitus patients in tinnitus patients and changes in biomarkers before and after treatment. the main questions it aims to answer are: * what are the biomarkers of tinnitus patients？ * how do these biomarkers change during treatment and is there a good correlation with behavioral outcomes? participants will be asked to complete audiological examination, tinnitus assessment, and magnetoencephalography examination, and they will receive sound therapy or repetitive transcranial magnetic stimulation therapy.

this study aims to use magnetoencephalography (meg) to collect the resting state responses before and after treatment in the control group, tinnitus patients in the acoustic stimulation treatment group, and rtms treatment group. firstly, compare the differences in power spectrum and brain functional connectivity indicators between tinnitus patients and normal control groups in different frequency bands, providing a theoretical basis for clinical diagnosis, precise positioning of tinnitus damaged areas, and understanding the pathogenesis of tinnitus; secondly, compare the electrophysiological functional indicators of tinnitus patients before and after treatment to reveal whether the damaged brain network can gradually reshape after treatment, and whether network information can serve as potential biomarkers to indicate the degree of tinnitus recovery; finally, compare the effectiveness differences between the two treatment methods, analyze their influencing factors, and provide guidance for frequency band precise intervention and rehabilitation of chronic tinnitus patients.

Eligibility criteria:
inclusion criteria: 1. subjective tinnitus lasting for more than 6 months, with a score of\>36 of the tinnitus disability inventory (thi)； 2. the otoscopy examination showed that the ear canal and eardrum were normal, and the tympanic impedance maps of both ears were type a, indicating that language ability met the requirements of language testing exclusion criteria: 1. family or congenital deafness history, ototoxicity drug use history, otitis media patients, etc 2. suffering from major physical diseases (sensory and motor disorders, neurological disorders, brain injuries, and other organic diseases) or mental disorders 3. the patient has aggressive behavior and an impulse to damage the device 4. metal in the body (including orthodontics, dental implants), tattoos, and heart stent surgery 5. having claustrophobia 6. contraindications to magnetic resonance examination
metalloproteinases and recurrent corneal erosion syndrome

Conditions: Recurrent Corneal Erosion Syndrome

Summary: recurrent corneal erosion (rce) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. this syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. this could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane. the investigators hypothesis is that episodes of rces are favored by a hyper- expression of matricial metalloprotease 9 (mmp-9) induced by emmprin and galectin-3. the identification of such induction could lead to development of therapeutics inhibiting emmprin and galectin- 3 in the rce syndrome.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * recurrent corneal erosion syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled * photorefractive surgical keratectomy (control patients) exclusion criteria: * opposition to participation in the study * known pregnancy or breast-feeding patient * no medical insurance coverage
capillary refill for assessment of dehydration

Conditions: Dehydration in Children

Summary: capillary refill is used clinically to assess multiple things in children. this is a prospective observational study of the correlation between capillary refill time and degree of dehydration in children seen in a pediatric ed.

all patient presenting to the pediatric er at ohsu less than 10 years are eligible to be enrolled if being seen for a condition putting them at risk for dehydration including emesis, diarrhea, etc. children will have their capillary refill time measured and then sent home with a digital scale to track their weight. this will serve as the standard for calculating percent dehydration. when a patient has reached a stable weight at 1 week we will assume this is their healthy weight. there is no intervention in the study.

Eligibility criteria:
inclusion criteria: * all children with chief complaint of diarrhea, emesis, nausea, abdominal pain exclusion criteria: * any child with chronic cardiac or pulm disease, raynauds syndrome, bilateral upper extremity trauma, previously enrolled in the study, already received ivf in the previous 48hrs, surgery within 1week, osteogenesis imperfecta.
a study of exg102-031 in patients with wamd (everest)

Conditions: Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Summary: in neovascular (wet) age-related macular degeneration (namd), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. this leakage affects the vision over time and can lead to severe blurriness or blinding. exg102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. before exg102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with namd.

age-related macular degeneration (amd) is a major cause of blindness and visual impairment in older adults. the wet form of amd, also called neovascular amd (namd) usually causes faster vision loss than the dry form. the most common current treatments of namd are products that inhibit vascular endothelial growth factor (vegf) (including ranibizumab (lucentis®, genentech) and aflibercept (eylea®, regeneron) and are delivered by intravitreal injections at 4 to 16 week intervals and continued indefinitely. this phase i, open-label, multiple-cohort, dose-escalation study is designed to evaluate the safety and tolerability of exg102-031 gene therapy in subjects with previously treated namd. safety will be assessed over 52 weeks after the administration of exg102-031.

Eligibility criteria:
inclusion criteria: 1. male or female, age ≥ 50 years of age; 2. diagnosis of namd and current active lesion in the study eye at screening; 3. an etdrs bcva letter scores between 73 and 19 letters in the study eye; 4. response to anti-vegf treatment during screening; 5. the study eye must be a pseudophakic lens (post-cataract surgery status); and 6. voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening. exclusion criteria: 1. presence of any ocular disease or history of disease in the study eye other than namd that may affect central visual acuity and/or macular detection, including retinal detachment, or in the opinion of the investigator could limit va improvement in the study eye; 2. presence in the study eye of cnv or macular edema due to causes other than amd; 3. presence in the study eye of scarring, fibrosis or atrophy involving the macula; 4. subretinal hemorrhage accumulating in the center of the macula of the test eye, with an area of hemorrhage ≥ 4 optic disc diameters; 5. active ocular infection in either eye; 6. presence of advanced glaucoma or uncontrolled glaucoma in the study eye; 7. history of intraocular surgery in the study eye within 90 days of screening; or 8. prior receipt of any ocular or systemic gene therapy agent.
effect of piperine in patients with oropharyngeal dysphagia

Conditions: Deglutition Disorders

Summary: piperine acts on the oropharyngeal trpv1, increasing sensory input and the release of substance p. these actions may accelerate the oropharyngeal swallow response, improving the swallowing of dysphagic patients.


Eligibility criteria:
inclusion criteria: * age\>18 * history of swallowing difficulties associated with aging and/or neurological diseases (neurodegenerative or non-progressive neurological diseases) * study explained and written subject information given * informed consent signed exclusion criteria: * patients suffering idiosyncratic phenomena or who are allergic to any medication, especially iodinated contrast media * patients suffering major respiratory disease or undergoing any type of surgery in the three months prior to the study * patients with a background of alcohol dependence or other drug dependence * currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of the study